Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05967351 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

Study acronym: EXPEDITION
StatusEnrolling by Invitation
PhasePhase 3
Started2023-09-27
View on ClinicalTrials.gov ↗

Amendment history

2026-02-04
Study Status, Study Description, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v13
Primary completion date2030-11-30→2033-10-31
Completion date2030-11-30→2033-10-31
Study sites37→38
Eligibility criteria-171 characters
[...] le and all other protocol requirements. Exclusion Criteria: ParticipantNot or family does not want to disclose participation with general practitioner/primary care physician and other medical providers. Other inclusion/exclusion criteria may apply.applicable
Secondary endpoints9 entries, revised
Change in the North Star Ambulatory Assessment (NSAA) Total Score From Pre-infusion Baseline to 5 Years Post-infusion of Delandistrogene Moxeparvovec to the End of the Study Participation Change in Time to Rise From Floor From Pre-infusion Baseline to 5 Years Post-infusion of Delandistrogene Moxeparvovec to the End of the Study Participation Change in the Time of 10-meter Walk/Run (10MWR) From Pre-infusion Baseline to 5 Years Post-infusion of Delandistrogene Moxeparvovec to the End of the Study Participation Change in Performance of Upper Limb (PUL) (Version 2.0) Total Scores From Pre-infusion [...] [...]
2025-01-15
Study Status, Contacts/Locations v12
Study sites36→37
2024-12-13
Study Status, Contacts/Locations v11
Study sites34→36
2024-11-15
Study Status, Contacts/Locations v10
Study sites31→34
2024-10-18
Study Status, Contacts/Locations v9
Study sites27→31
Show 8 earlier versions
2024-09-17
Study Status, Contacts/Locations v8
Study sites21→27
2024-08-01
Study Status, Contacts/Locations v7
Study sites15→21
2024-06-20
Study Status, Contacts/Locations v6
Study sites11→15
2024-05-15
Study Status, Contacts/Locations v5
Study sites7→11
2024-04-19
Study Status, Contacts/Locations v4
Study sites5→7
2024-02-21
Study Status, Contacts/Locations v3
Study sites4→5
2023-12-20
Study Status, Contacts/Locations v2
Study sites2→4
2023-10-26
Not Yet Recruiting→Enrolling by Invitation Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Enrolling by Invitation
Start dateestimated 2023-08-31→confirmed 2023-09-27
Study sitescontacts updated at 2 of 2 sites
2023-07-21
Original filing
The purpose of this study is to provide a single clinical study with a uniform approach to monitoring long-term safety and efficacy in participants who received delandistrogene moxeparvovec in a previous clinical study. No study drug will be administered as part of this study.
Trial Details
NCT Number NCT05967351
Lead Sponsor Sarepta Therapeutics, Inc.
Collaborators: Hoffmann-La Roche
Conditions Duchenne Muscular Dystrophy
Enrollment 400 participants
Start Date 2023-09-27
Primary Completion 2033-10-31 (estimated)
Study Completion 2033-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-06